Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
... GHENT, Belgium, 2 July, 2007 -- ablynx today announced positive interim results from the ongoing Phase I study of ...eted therapies in the form of significantly reduced bleeding complications. ablynx has demonstrated a large therapeutic window for ALX-0081 based on the high ...RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer
... the Janssen Research Foundation in Belgium. Dr. Cauwenbergh currently serves as a Board member of DARA Biosciences, Upstream Biosciences as well as ablynx NV, and is a member of the Board of Trustees, and Vice Chairman of Bio New Jersey. Since 2004, Dr. Cauwenbergh has served as Official Trade Advisor fo...Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
...h representatives in London and Madrid. Companies that Gilde Healthcare Partners has pro-actively supported span all aspects of healthcare and include ablynx (Belgium), Agendia (Netherlands), AMT (Netherlands), Chroma Therapeutics (UK), Glycart (Switzerland), Innate Pharma (France) and Symphogen (Denmark). ...Bioentrepreneur - Start-up Profiles - Ablynx
Bioentrepreneur: Comprehensive information on biotechnology startups ... Belgian biotech company Ablynx (Zwijnaarde) is developing a rare type of ...ABLYNX PROMOTED TO THE BELGIAN MID-CAP INDEX
Ablynx is developing a portfolio of Nanobody ... Ablynx has ongoing research collaborations and significant partnerships with ...ABLYNX ANNOUNCES 2008 FULL YEAR RESULTS
Post year-end, Ablynx published important initial data on a ... to continue to develop Ablynx as one of the most exciting biotechnology companies in Europe. ...Ablynx Extends Drug Discovery Alliance with Novartis
Ablynx announced that its drug discovery and development alliance with Novartis has been extended for another year. ... collaboration Ablynx receives license ...